Physiological activity of sugarcane after the application of pre-emergence herbicides

Objetivou-se neste trabalho avaliar as características fisiológicas da cana-de-açúcar após aplicação de herbicidas em pré-emergência. Para isso, foi conduzido um experimento em esquema fatorial 2x5, onde o fator A constituiu-se das cultivares RB 867515 e SP 81-3250, e o fator B da aplicação em pré-emergência do tebuthiuron, diuron, ametryn, a mistura formulada diuron + hexazinone e uma testemunha sem herbicidas. O delineamento utilizado foi inteiramente casualizado, com quatro repetições. As avaliações foram realizadas aos 90 dias após a aplicação dos herbicidas. A concentração interna de carbono (Ci), a relação carbono interno e externo (Ci/Ca) e o índice SPAD das cultivares de cana-de-açúcar não foram afetadas pela aplicação em pré-emergência dos herbicidas. No entanto, a condutância estomática (gs), a taxa respiratória (E) e a taxa fotossintética (A) da RB 867515 foram reduzidas quando tratadas com tebuthiuron. A A e a eficiência no uso da água (EUA) da cultivar RB 867515 foi alterada negativamente pela aplicação do ametryn. Conclui-se que existe diferença na sensibilidade dos genótipos de cana-de-açúcar aos herbicidas, sendo que a SP 81-3250 mostrou-se mais tolerante. A aplicação do ametryn e tebuthiuron reduz a A da RB 867515.The objective of this study was to evaluate the physiological characteristics of sugarcane after application of pre-emergence herbicides. For this, an experiment was conducted in a 2x5 factorial scheme, where the first factor consisted of cultivates RB 867515 and SP 81-3250, and factor B of the pre-emergence application of tebuthiuron, diuron, ametryn, a formulated mixture diuron + hexazinone and a control without herbicides. The experimental design was completely randomized, with four replications. The internal concentration of carbon (Ci), internal and external carbon (Ci/Ca) and SPAD index of cultivars of sugarcane ratio were not affected by the application of pre-emergence herbicides. However, stomatal conductance (gs), respiratory rate (E) and the photosynthetic rate (A) were reduced when treated with tebuthiuron. The A and efficiency of water use (U.S.) cultivar RB 867515 was negatively altered by the application of ametryn. It is concluded that a difference in sensitivity of the genotypes of sugar cane herbicide, and the SP 81-3250 was more tolerant. The application of tebuthiuron and ametryn reduces the A of RB 867515

Digestible lysine levels for barrows with high genetic potencial from 95 to 125 kg

Avaliou-se o efeito de níveis de lisina digestível sobre o desempenho e a composição de carcaça de suínos machos castrados de alto potencial genético para deposição de carne. Foram utilizados 80 animais com peso inicial de 95,55 ± 1,04 distribuídos em delineamento experimental de blocos ao acaso, com cinco dietas (0,540; 0,642; 0,744; 0,846 e 0,948% de lisina digestível), oito repetições e dois animais por unidade experimental. As dietas experimentais e água foram fornecidas à vontade durante todo o período experimental. Os níveis de lisina digestível não influenciaram o consumo de ração diário e o peso de carcaça dos animais. O ganho de peso diário e a conversão alimentar melhoraram de forma quadrática até os níveis de lisina digestível estimados de 0,803 e 0,817%, respectivamente. Foi observado efeito linear crescente dos tratamentos sobre o consumo diário de lisina e sobre a quantidade de carne. Embora, a deposição diária de carne tenha aumentado de forma linear, o modelo LRP foi o que melhor se ajustou aos dados que permaneceram em um platô a partir do nível de lisina digestível de 0,803%. Os níveis de lisina digestível influenciaram a espessura de toucinho P2 dos animais que reduziu de forma linear. O nível de lisina digestível de 0,803%, que corresponde a consumo de 24,60 g/dia de lisina digestível, proporciona os melhores resultados de ganho de peso e deposição de carne, enquanto o nível de 0,817%, correspondente a consumo de 25,03 g/dia de lisina, proporciona melhor conversão alimentar e o de 0,948%, correspondente a consumo de 29,09 g/dia de lisina digestível, promove maior deposição de carne e espessura de toucinho em suínos machos castrados na fase dos 95 aos 125 kg.This work evaluated levels of digestible lysine on performance and carcass composition of barrows with high genetic potential for meat deposition. It was used 80 animals with initial body weight of 95.55 ± 1.04 kg, distributed in a completely randomized block design, with 5 diets (0.540; 0.642; 0.744; 0.846 and 0.948% of digestible lysine), eight replicates and two animals per experimental unit. The experimental diets and water were provided ad libitum throughout the experimental period. Digestible lysine levels did not change daily feed intake and carcass weight of the animals. Daily weight gain and feed conversion improved in a quadratic way up to the estimated levels of 0.803 and 0.871% of digestible lysine, respectively. It was observed an increasing linear effect of the treatments on daily lysine intake and amount of meat. Although daily meat deposition had increased in a linear way, the LRP was the model that best adjusted to the data which remained on a plateau from 0.803% of digestible lysine level. The levels of digestible lysine influenced the P2 backfat thickness of the animals which decreased in a linear way. The digestible lysine level of 0.803%, corresponding to an intake of 24.60 g/day of digestible lysine provides the best results of weight gain and meat deposition whereas the level of 0.817% corresponding to an intake of 25.30 g/day of lysine provides the best result of feed conversion, and the digestible lysine level of 0.948% corresponding to an intake of 29.09 g/day of digestible lysine provides the best results of meat deposition and backfat thickness of barrows from 95 to 125 kg

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362